Literature DB >> 26629322

DNA microarray unravels rapid changes in transcriptome of MK-801 treated rat brain.

Yuka Kobayashi1, Sofya P Kulikova1, Junko Shibato1, Randeep Rakwal1, Hiroyuki Satoh1, Didier Pinault1, Yoshinori Masuo1.   

Abstract

AIM: To investigate the impact of MK-801 on gene expression patterns genome wide in rat brain regions.
METHODS: Rats were treated with an intraperitoneal injection of MK-801 [0.08 (low-dose) and 0.16 (high-dose) mg/kg] or NaCl (vehicle control). In a first series of experiment, the frontoparietal electrocorticogram was recorded 15 min before and 60 min after injection. In a second series of experiments, the whole brain of each animal was rapidly removed at 40 min post-injection, and different regions were separated: amygdala, cerebral cortex, hippocampus, hypothalamus, midbrain and ventral striatum on ice followed by DNA microarray (4 × 44 K whole rat genome chip) analysis.
RESULTS: Spectral analysis revealed that a single systemic injection of MK-801 significantly and selectively augmented the power of baseline gamma frequency (30-80 Hz) oscillations in the frontoparietal electroencephalogram. DNA microarray analysis showed the largest number (up- and down- regulations) of gene expressions in the cerebral cortex (378), midbrain (376), hippocampus (375), ventral striatum (353), amygdala (301), and hypothalamus (201) under low-dose (0.08 mg/kg) of MK-801. Under high-dose (0.16 mg/kg), ventral striatum (811) showed the largest number of gene expression changes. Gene expression changes were functionally categorized to reveal expression of genes and function varies with each brain region.
CONCLUSION: Acute MK-801 treatment increases synchrony of baseline gamma oscillations, and causes very early changes in gene expressions in six individual rat brain regions, a first report.

Entities:  

Keywords:  Dizocilpine; Dye-swap; Gene expression; MK801; Microarray; N-Methyl-D-aspartate receptors

Year:  2015        PMID: 26629322      PMCID: PMC4657125          DOI: 10.4331/wjbc.v6.i4.389

Source DB:  PubMed          Journal:  World J Biol Chem        ISSN: 1949-8454


  88 in total

Review 1.  [Dysfunction of glutamatergic systems and potential animal models of schizophrenia].

Authors:  Akihiro Mouri; Yukihiro Noda; Hiroyuki Mizoguchi; Toshitaka Nabeshima
Journal:  Nihon Yakurigaku Zasshi       Date:  2006-01

2.  Dopamine increases inhibition in the monkey dorsolateral prefrontal cortex through cell type-specific modulation of interneurons.

Authors:  Sven Kröner; Leonid S Krimer; David A Lewis; Germán Barrionuevo
Journal:  Cereb Cortex       Date:  2006-06-13       Impact factor: 5.357

3.  Anticonvulsant and behavioral effects of two novel competitive N-methyl-D-aspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindling model of epilepsy. Comparison with MK-801 and carbamazepine.

Authors:  W Löscher; D Hönack
Journal:  J Pharmacol Exp Ther       Date:  1991-02       Impact factor: 4.030

4.  A single application of MK801 causes symptoms of acute psychosis, deficits in spatial memory, and impairment of synaptic plasticity in rats.

Authors:  Denise Manahan-Vaughan; Dorothea von Haebler; Christine Winter; Georg Juckel; Uwe Heinemann
Journal:  Hippocampus       Date:  2008       Impact factor: 3.899

5.  Long term exposure to the chemokine CCL2 activates the nigrostriatal dopamine system: a novel mechanism for the control of dopamine release.

Authors:  A Guyon; D Skrzydelski; I De Giry; C Rovère; G Conductier; J M Trocello; V Daugé; P Kitabgi; W Rostène; J L Nahon; S Mélik Parsadaniantz
Journal:  Neuroscience       Date:  2009-05-27       Impact factor: 3.590

6.  MK-801, a proposed noncompetitive antagonist of excitatory amino acid neurotransmission, produces phencyclidine-like behavioral effects in pigeons, rats and rhesus monkeys.

Authors:  W Koek; J H Woods; G D Winger
Journal:  J Pharmacol Exp Ther       Date:  1988-06       Impact factor: 4.030

7.  N-methyl-D-aspartate receptor antagonist effects on prefrontal cortical connectivity better model early than chronic schizophrenia.

Authors:  Alan Anticevic; Philip R Corlett; Michael W Cole; Aleksandar Savic; Mark Gancsos; Yanqing Tang; Grega Repovs; John D Murray; Naomi R Driesen; Peter T Morgan; Ke Xu; Fei Wang; John H Krystal
Journal:  Biol Psychiatry       Date:  2014-07-31       Impact factor: 13.382

Review 8.  Rationale for and use of NMDA receptor antagonists in Parkinson's disease.

Authors:  Penelope J Hallett; David G Standaert
Journal:  Pharmacol Ther       Date:  2004-05       Impact factor: 12.310

9.  Manners of arginine vasopressin secretion in schizophrenic patients--with reference to the mechanism of water intoxication.

Authors:  T Kishimoto; M Hirai; H Ohsawa; M Terada; I Matsuoka; G Ikawa
Journal:  Jpn J Psychiatry Neurol       Date:  1989-06

10.  Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans.

Authors:  N R Driesen; G McCarthy; Z Bhagwagar; M Bloch; V Calhoun; D C D'Souza; R Gueorguieva; G He; R Ramachandran; R F Suckow; A Anticevic; P T Morgan; J H Krystal
Journal:  Mol Psychiatry       Date:  2013-01-22       Impact factor: 15.992

View more
  3 in total

1.  Mapping Molecular Datasets Back to the Brain Regions They are Extracted from: Remembering the Native Countries of Hypothalamic Expatriates and Refugees.

Authors:  Arshad M Khan; Alice H Grant; Anais Martinez; Gully A P C Burns; Brendan S Thatcher; Vishwanath T Anekonda; Benjamin W Thompson; Zachary S Roberts; Daniel H Moralejo; James E Blevins
Journal:  Adv Neurobiol       Date:  2018

Review 2.  Smell and Stress Response in the Brain: Review of the Connection between Chemistry and Neuropharmacology.

Authors:  Yoshinori Masuo; Tadaaki Satou; Hiroaki Takemoto; Kazuo Koike
Journal:  Molecules       Date:  2021-04-28       Impact factor: 4.411

Review 3.  A Neurophysiological Perspective on a Preventive Treatment against Schizophrenia Using Transcranial Electric Stimulation of the Corticothalamic Pathway.

Authors:  Didier Pinault
Journal:  Brain Sci       Date:  2017-03-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.